Further, in preclinical animal studies, pharmacological approaches designed to reduce GSK3 activity have been shown to reduced AD-like pathology, including Aβ production, tau hyperphosphorylation and the associated cognitive impairments [181–183]. This evidence concerns the gene MAPT and Alzheimer disease.